Xarelto Bleeding Injury $28M Verdict Tossed. What the court giveth, the court taketh away! Such is the capriciousness of the court system.
The first Xarelto Bleeding Injury plaintiff’s victory against Bayer and Johnson & Johnson (J&J) over Xarelto’s bleeding risks was short lived. In the case of Lynn Hartman, Judge Michael Erdos in Philadelphia this week entered a judgment notwithstanding the verdict, stating that a no reasonable jury could have reached the same conclusion.
The judge tanked the verdict after hearing arguments from Johnson & Johnson and it’s Janssen unit and Bayer that a physician for the plaintiff had testified that additional warnings would not have changed her decision to prescribe the drug.
Xarelto Bleeding Injury Verdict $28M
The Philadelphia jury slammed the companies, which jointly developed the blockbuster blood thinner drug, with $1.8 million in compensatory and $26 million in punitive damages, to punish the companies for their bad behavior.
The plaintiff’s verdict was the first defense trial loss in personal injury and product liability litigation over Xarelto. Bayer and J&J have won four consecutive trials in federal court.
The original verdict in December was the first state case to go against Bayer and J&J in their defense of the blockbuster blood thinner. Xarelto is facing liability from thousands of plaintiffs claiming it can cause serious bleeding and that the drugmakers didn’t appropriately warn patients and physicians.
Hartman in her Xarelto injury claim alleged that her Xarelto medication use, to prevent strokes associated with her atrial fibrillation heart condition, lead to severe gastrointestinal bleeding. The case was the first to go to trial in state courts over Xarelto bleeding risks.
Huge Nationwide Xarelto Injury Litigation
J&J, the world’s largest pharmaceutical and medical device maker is exposed to over 21,000 Xarelto liability cases, according to its most recent business quarterly filing. About 1,400 lawsuits are consolidated in Philadelphia state court according to reports. Xarelto, an anticoagulant or blood thinner drug was initially approved by the FDA in 2011.
Xarelto is a blockbuster drug with over a $billion in sales. Xarelto was Bayer’s top-selling drug in 2017, with $3.24 billion in revenues, and it accounts for being the third best selling medication for J&J at $2.5 billion in sales.
If you or a loved one used Xarelto and have suffered injuries or wrongful death with the medication, contact the Dr. Shezad Malik Law Firm to learn more about your legal rights. You can speak with one of our team by calling toll-free at 214-390-3189, 214-390-3189 or by filling out the case evaluation form on this page.
Read more here